Zyversa Therapeutics Stock Investor Sentiment

ZVSA Stock   1.11  0.02  1.77%   
About 63% of ZyVersa Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding ZyVersa Therapeutics suggests that many traders are alarmed. The current market sentiment, together with ZyVersa Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ZyVersa Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

ZyVersa Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards ZyVersa Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at www.macroaxis.com         
Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3
Macroaxis News
few days ago at news.google.com         
ZyVersa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept...
Google News at Macroaxis
few days ago at gurufocus.com         
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC ...
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc
Gurufocus Stories at Macroaxis
over a week ago at globenewswire.com         
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Macroaxis News: globenewswire.com
over a week ago at thelincolnianonline.com         
ZyVersa Therapeutics, Inc. Short Interest Update
news
over two weeks ago at finance.yahoo.com         
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibitio...
Yahoo News
over two weeks ago at benzinga.com         
Dow Jumps 400 Points Yum Brands Posts Downbeat Earnings
benzinga news
over three weeks ago at globenewswire.com         
ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the I...
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammati...
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Deve...
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Cur...
Macroaxis News: globenewswire.com
over a month ago at globenewswire.com         
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC ...
Macroaxis News: globenewswire.com
over a month ago at thelincolnianonline.com         
Critical Analysis ZyVersa Therapeutics Sunshine Biopharma
news
over two months ago at www.macroaxis.com         
Acquisition by Oconnor Daniel J. of 1750 shares of ZyVersa Therapeutics subject to Rule 16b-3
Macroaxis News
Far too much social signal, news, headlines, and media speculation about ZyVersa Therapeutics that are available to investors today. That information is available publicly through ZyVersa media outlets and privately through word of mouth or via ZyVersa internal channels. However, regardless of the origin, that massive amount of ZyVersa data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ZyVersa Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ZyVersa Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ZyVersa Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ZyVersa Therapeutics alpha.

ZyVersa Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
ZyVersa Therapeutics files for mixed shelf offering
09/03/2024
2
Acquisition by Oconnor Daniel J. of 1750 shares of ZyVersa Therapeutics subject to Rule 16b-3
09/25/2024
3
ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
10/07/2024
4
ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases
10/22/2024
5
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progr...
11/05/2024
6
Anson Funds Management LP Acquires New Stake in ZyVersa Therapeutics Inc
11/15/2024
7
Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3
11/22/2024

Complementary Tools for ZyVersa Stock analysis

When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data